

CME Symposium

FRIDAY, SEPTEMBER 9

2:30 PM – 3:00 PM

Closing the Gaps in the Diagnosis and Management of Aortic Stenosis in Women: The Role of TAVR in Improving Outcomes



This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Edwards Lifesciences LLC.

PROGRAM OVERVIEW:

There are significant gaps in the diagnosis, evaluation and treatment of women with aortic stenosis (AS). Women with symptomatic, severe AS, are significantly less likely than men to receive treatment with any AVR (aortic valve replacement) procedure, and have worse outcomes with SAVR (surgical aortic valve replacement) compared to men. On the other hand, TAVR (transcatheter aortic valve replacement) has been shown to lead to better outcomes in women compared to men, however, significant disparities in treatment persist despite a recent increase in the use of TAVR in women. This session will highlight some of these disparities, as well as review the benefits of TAVR in women with AS.

LEARNING OBJECTIVES:

After completing this activity, the participant should be better able to:

- Recognize the impacts, differences in symptom presentation, and clinical significance of aortic stenosis in women.
- Outline tailored strategies to screen, diagnose, and risk stratify women with aortic stenosis as a means to identify patient candidates who may benefit from appropriate treatment.
- Summarize the updated guidelines and evidence from recent clinical trials and real-world studies of TAVR vs. SAVR in women with AS across the risk continuum.
- Develop individualized treatment plans for women with severe aortic stenosis based on updated evidence, guidelines, and patient-specific clinical presentation and needs.

FACULTY



Kimberly A. Skelding, MD

Interventional Cardiologist, Confluence Health
Wenatchee, WA

Closing the Gaps in the Diagnosis and Management of Aortic Stenosis in Women: The Role of TAVR in Improving Outcomes

JOINT PROVIDERSHIP STATEMENT



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION

PACE designates this live activity for a maximum of 0.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACIST CONTINUING EDUCATION

PACE designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number -JA4008073-9999-22-177-L01-P. Type of Activity: Knowledge

HOW TO REQUEST CE CREDIT

An evaluation link will be provided post-meeting to all attendees of the Masterclass. Several email reminders will be sent post-meeting. **Please claim your CE credits by completing the evaluation by Friday, September 30, 2022.**

Upon completion of the CME/CE evaluation, attendees can download their general sessions certificate. For satellite symposia, certificates will be provided separately via email within 5-7 business days after the September 30 deadline.

For Pharmacists: Pharmacists have until the September 30 deadline to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Expect credit uploads to be completed within 5-7 business days after the evaluation deadline.

For questions regarding the evaluation, please contact: cmhc_eval@cardiometabolicealth.org

DISCLOSURES

Information on planner and faculty disclosure is available by following [this link](#).

DISCLOSURE OF CONFLICT OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

**Closing the Gaps in the Diagnosis and Management of Aortic Stenosis in Women:
The Role of TAVR in Improving Outcomes**

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.